Accessibility Menu
NovoCure logo

NovoCure

(NASDAQ) NVCR

Current Price$17.15
Market Cap$1.83B
Since IPO (2015)-14%
5 Year-91%
1 Year-4%
1 Month+9%

NovoCure Financials at a Glance

Market Cap

$1.83B

Revenue (TTM)

$674.41M

Net Income (TTM)

-$173.05M

EPS (TTM)

-$1.53

P/E Ratio

-10.28

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$17.15

Volume

61,469

Open

$15.87

Previous Close

$17.15

Daily Range

$15.87 - $17.28

52-Week Range

$9.82 - $18.92

Estimated Earnings Date

Jul 23, 2026

NVCR: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NovoCure

Industry

Healthcare Equipment and Supplies

Employees

1,605

CEO

Frank Leonard

Headquarters

Baar, 6340, CH

NVCR Financials

Key Financial Metrics (TTM)

Gross Margin

75.20%

Operating Margin

-27.19%

Net Income Margin

-25.66%

Return on Equity

-50.82%

Return on Capital

-24.39%

Return on Assets

-21.96%

Earnings Yield

-9.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.83B

Shares Outstanding

115.82M

Volume

61.47K

Avg. Volume

1.64M

Financials (TTM)

Gross Profit

$507.13M

Operating Income

-$183.36M

EBITDA

-$155.38M

Operating Cash Flow

-$26.88M

Capital Expenditure

-$21.19M

Free Cash Flow

-$48.07M

Cash & ST Invst.

$441.80M

Total Debt

$234.94M

NovoCure Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$174.06M

+12.3%

Gross Profit

$135.13M

+16.0%

Gross Margin

77.63%

N/A

Market Cap

$1.83B

N/A

Market Cap/Employee

$1.14M

N/A

Employees

1,605

N/A

Net Income

-$71.14M

-107.3%

EBITDA

-$63.30M

-134.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$441.80M

-52.6%

Total Debt

$234.94M

-66.3%

Accounts Receivable

$93.27M

-21.3%

Inventory

$43.46M

+10.1%

Long Term Debt

$234.94M

+70.5%

Short Term Debt

$0.00

-100.0%

Return on Assets

-21.96%

N/A

Return on Invested Capital

-32.15%

N/A

Free Cash Flow

-$18.67M

+59.7%

Operating Cash Flow

-$13.52M

+62.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TDOCTeladoc Health, Inc.
$9.20+1.10%
PLSEPulse Biosciences, Inc.
$29.21+3.09%
NEOGNeogen Corporation
$9.34+0.32%
KMTSKestra Medical Technologies, Ltd.
$26.98+2.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.92-0.01%
TAT&T
$20.58+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.30-0.15%
CLROClearOne
$6.48+1.01%

Questions About NVCR

What is the current price of NovoCure?

NovoCure is trading at $17.15 per share.

What is the 52-week range for NovoCure?

Over the past 52 weeks, NovoCure has traded between $9.82 and $18.92.

How much debt does NovoCure have?

As of the most recent reporting period, NovoCure reported total debt of $234.94M.

How much cash does NovoCure have on hand?

NovoCure reported $97.32M in cash and cash equivalents in its most recent financial results.

What is NovoCure’s dividend yield?

NovoCure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.